The brand name for viloxazine is Qelbree [1].
What is Qelbree used for?
Qelbree is a medication prescribed for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years [1].
How does Qelbree work?
Qelbree is a selective norepinephrine reuptake inhibitor (SNRI) [1]. It works by increasing the levels of norepinephrine, a neurotransmitter, in the brain [2]. Norepinephrine plays a role in regulating mood, attention, and behavior [2].
When did Qelbree become available?
Qelbree was approved by the U.S. Food and Drug Administration (FDA) in April 2021 [1].
Who makes Qelbree?
Qelbree is manufactured by Supernus Pharmaceuticals [1].
What are the potential side effects of Qelbree?
Common side effects of Qelbree can include somnolence (drowsiness), insomnia, decreased appetite, nausea, vomiting, diarrhea, and fatigue [1]. In some cases, Qelbree has been associated with an increased risk of suicidal thoughts and behaviors. Patients taking Qelbree should be monitored for any new or worsening symptoms of depression, suicidal thoughts, or unusual changes in behavior [1][3]. There is also a warning about potential heart rate and blood pressure increases [1].
Are there alternatives to Qelbree for ADHD treatment?
Yes, there are several other medications available for ADHD treatment. These include stimulant medications, such as methylphenidate and amphetamine, and non-stimulant medications like atomoxetine, guanfacine, and clonidine [4]. Viloxazine was previously marketed under the brand name Vivalan for depression in Europe, but Qelbree is specifically formulated and indicated for ADHD in the United States [5][1].
What is the patent status for viloxazine (Qelbree)?
Information regarding the patent status and expiry dates for viloxazine, including Qelbree, can be found on DrugPatentWatch.com [6].
Sources:
1. Supernus Pharmaceuticals. Qelbree (viloxazine extended-release capsules) Prescribing Information. [Link to Qelbree Prescribing Information, if available publicly and with appropriate citation formatting for a drug label, otherwise omit or cite manufacturer's product page.]
2. National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder. [Link to NIMH ADHD page, if applicable and cited]
3. FDA. FDA Drug Safety Communication. [Link to relevant FDA safety announcement, if available]
4. Mayo Clinic. Attention-deficit/hyperactivity disorder (ADHD) in children. [Link to Mayo Clinic ADHD page, if applicable and cited]
5. European Medicines Agency. Viloxazine. [Link to EMA viloxazine page, if applicable and cited]
6. DrugPatentWatch.com. [Link to DrugPatentWatch.com, if the site is directly browsed for specific patent info]